An interventional study of eprosartan/HCTZ in Hypertension and Type 2 Diabetes, sponsored by Solvay Pharmaceuticals. Completed at 63 sites in 9 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-01-30.
Sponsored by Solvay Pharmaceuticals · Not applicable, Interventional, and Treatment
This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 440 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Solvay Pharmaceuticals is the lead sponsor of 84 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Blood pressure reduction
Comparison of responder rates
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Solvay Pharmaceuticals